Rare

Innovative Therapies Deserve Innovative Strategies

With over 7,000 distinct types of rare and genetic diseases affecting more than 400 million individuals globally, regenerative medicine represents a promising avenue for developing cures. This field is poised to revolutionize healthcare by shifting from conventional treatment models to curative therapy models. The advancement of new technologies, combined with the emergence of companies offering innovative products and treatments, positions regenerative medicine as one of the fastest-growing areas of research with significant potential for commercial success and improved patient outcomes. 

Enhance Patient Experiences and Deliver Effective Therapies Globally 

Manufacturers of rare and orphan drugs are increasingly aware that innovative models and approaches are required for a successful product launch. At EVERSANA, we understand the complexities of developing products for small populations with global reach. 

We have developed a comprehensive commercialization model designed to reach small populations, ensuring that patients are identified, diagnosed, onboarded, and adhere to their therapies. EVERSANA COMPLETE Commercialization® addresses common friction points and barriers in the process, facilitates the management of new product launches, and enables swift access to global patient populations. We tailor strategies to specific therapies and patient needs while managing go-to-market expenses effectively. This approach allows manufacturers to move beyond traditional models and revolutionize the commercialization of complex drugs globally, resulting in a personalized and impactful patient experience. 

Achieve Operational Rigor in Rare Disease 

EVERSANA’s advanced commercialization strategy integrates various functional areas to achieve operational efficiency for manufacturers and expedite the introduction of therapies. This includes appropriately sizing field medical teams, establishing hub programs, and coordinating the distribution of therapies and resources to support partners and patients effectively. 

Challenges We Address

• Innovative changes impacting rare disease community in research, clinical development, manufacturing, and commercial models 
• Developing economic models to demonstrate value of subsidizing healthcare costs 
• Finding patients and designing collaborative clinical trials 
• Establishing informed sales and marketing plans 
• Accurate forecasting for market access 
• Optimizing supply chain management 
• Addressing challenges with copays, authorizations, complex therapies, and education on side effects 
• Managing limited production cycles to reduce waste and ensure availability 
• Overcoming patient onboarding and adherence issues 

Leverage Artificial Intelligence to Enhance Patient Identification 

The demand for data intensifies as diagnosis becomes increasingly time-sensitive and the development pipeline for innovative therapies continues to expand. With this growth, manufacturers bear the responsibility to consider ways to expedite the diagnostic process to better serve patients. 

Rare disease diagnosis delays often stem from limited provider experience. Providers encountering few rare cases annually or in their careers may struggle to identify these patients within HIPAA-compliant data. 

We utilize the most comprehensive global tools for data analysis, international health economic studies, and advanced AI-enabled technologies and machine learning models. This approach helps expedite diagnosis, identify undiagnosed populations, reach patients, improve access to therapy, and facilitate positive outcomes. 

Harness the Power of Data to Inform the Patient Journey 

Through machine learning that integrates various data sets, manufacturers can gain better insights into patient journeys and disease progression. By using real-world data (RWD) to generate real-world evidence (RWE) from sources like electronic medical records, claims, and physician and non-clinical data, manufacturers can inform the entire patient journey. This enables a data-driven approach to patient care. Aggregated data allows manufacturers to provide providers with the information needed for a comprehensive and efficient diagnostic process.